- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05819749
Diabetes Homelessness Medication Support Program in Spanish (DH-Spanish)
Expanding the Diabetes Homelessness Medication Support (D-Homes) Program to Spanish Speaking Hispanics
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study has an overall goal to modify and pilot test a previously developed collaborative care intervention using motivational interviewing and behavioral activation alongside education and psychosocial support to improve medication adherence tailored to the experiences of people experiencing homelessness and diabetes (DH). The intervention was developed in English. This study is intended to test the modified intervention for DH who speak Spanish (DH-SH). The study team's central hypothesis is that medication adherence and diabetes self-care (and eventual glycemic control, health care use/cost) will improve with an intervention tailored to the unique context of DH-SH.
This protocol tests patient perceptions of the feasibility and acceptability of study procedures and refines the D-Homes treatment manual through test cases (n=12). The study team hypothesizes that the D-Homes manual and study procedures will be feasible and acceptable to DH-SH as measured by self-report and post-treatment interview.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- Hennepin Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 yrs or older
- Spanish-speaking
Recent homelessness by federal definition (HEARTH ACT)
- Any housing instability in the last 12 mo. (includes supported housing or worry about paying rent)
- Significant housing instability in the last 24 mos. (includes any stay in shelter, outside, or places not meant for human habitation)
- Self-reported diagnosis of type 2 diabetes, later verified in medical record
- Plan to stay in local area or be reachable by phone for the next 16 weeks
- Willingness to work on medication adherence and diabetes self-care
Exclusion Criteria:
- Inability to provide informed consent (e.g. presence of a legal guardian, prisoners)
- Active psychosis or intoxication precluding ability to give informed consent
- Pregnant or lactating females
- Patients who choose to opt out of research
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DH-Spanish Intervention
Behavioral treatment by a diabetes wellness coach.
|
There will be 10 sessions offered within 12 weeks to participants.
Sessions will last 30-60 minutes.
During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care.
The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing.
The coach will also help with resources and care coordination.
The coach will also provide brief diabetes education as needed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of intervention
Time Frame: at 16 weeks
|
Client Satisfaction Questionnaire, 8-item version, with a score range from 8-32, higher score indicating higher satisfaction.
|
at 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in glycemic control
Time Frame: Baseline to 16 weeks
|
We will measure glycemic control using hemoglobin A1c.
This will be done on a consistent, validated point-of-care machine using blood samples collected via venipuncture.
We will compare glycemic control from baseline to 16 weeks.
|
Baseline to 16 weeks
|
Health-related quality of life
Time Frame: Baseline to 16 weeks
|
As measured by the SF-12, a 12-question questionnaire.
The SF-12 is analyzed for two summary scores - the physical component score (PCS-12) and the mental component score (MCS-12).
The average score of each component is 50 for people in the United States, with a standard deviation of 10 points.
|
Baseline to 16 weeks
|
Diabetes medication adherence
Time Frame: Baseline to 16 weeks
|
As measured by the Adherence to Refills and Medications Scales-Diabetes (ARMS-D), Total scores range from 12-48, with higher values indicating worse outcomes.
We will compare ARMS-D scores from baseline to 16 weeks.
|
Baseline to 16 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Katherine D Vickery, MD, Hennepin Healthcare Research Institute
Publications and helpful links
General Publications
- Nguyen TD, Attkisson CC, Stegner BL. Assessment of patient satisfaction: development and refinement of a service evaluation questionnaire. Eval Program Plann. 1983;6(3-4):299-313. doi: 10.1016/0149-7189(83)90010-1.
- Mayberry LS, Gonzalez JS, Wallston KA, Kripalani S, Osborn CY. The ARMS-D out performs the SDSCA, but both are reliable, valid, and predict glycemic control. Diabetes Res Clin Pract. 2013 Nov;102(2):96-104. doi: 10.1016/j.diabres.2013.09.010. Epub 2013 Sep 26.
- Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Qual Life Res. 1998 Feb;7(2):155-66. doi: 10.1023/a:1008809610703.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-FY2023-556
- R03DK133553 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
DiabeloopUniversity Hospital, Grenoble; AGIR à Dom; Icadom; Centre Hospitalier Annecy Genevois and other collaboratorsCompletedDiabetes Mellitus Type 2 - Insulin-TreatedFrance
Clinical Trials on Diabetes Homelessness Medication Support Program in Spanish
-
Stanford UniversityCompleted
-
Hennepin Healthcare Research InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedType 2 Diabetes | Homeless PersonsUnited States
-
Hennepin Healthcare Research InstituteNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Psychological Distress | Housing ProblemsUnited States
-
Kaiser PermanenteCompleted
-
Omada Health, Inc.Palo Alto Medical Foundation; Sutter HealthTerminatedType 2 DiabetesUnited States
-
Joslin Diabetes CenterCompletedObesity | Diabetes Mellitus, Type 2United States
-
Kaiser PermanenteCompletedObesity | Diabetes Mellitus, Type 2 | OverweightUnited States
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2United States
-
Vanderbilt UniversityNationwide Children's HospitalTerminatedPediatric CancerUnited States
-
UnitedHealth GroupComcast Corporation; Dr. Ron AckermannCompleted